Essilor International, the French ophthalmic optics company that designs, manufactures and distributes lenses, was fined by the French Competition Authority (FCA). The company will have to shell out €81 million to settle the penalty with the antitrust regulators in France.
According to Reuters, the FCA handed down its decision to Essilor for alleged unfair business practices. The competition watchdog said that the fine was for the violations that stretch over 11 years.
The authorities explained this week that optic lens maker’s actions had been mapped out to impede the development of online sales for corrective lenses in France. EssilorLuxottica, Essilor’s parent company, will pay €15 million out of the total penalty of €81 million.
The Autorite de la Concurrence said EssilorLuxottica and its Essilor International engaged in practices that blocked online sales of some prescription lenses in the country. The antitrust regulator determined that Essilor abused its dominant position in the lenses distribution market this move has become an obstruction in the growth of online sales of other eye-corrective lens and eyeglasses firms such as DirectOptic, Sensee, and Happyview.
Market Watch reported that as early as 2009, Essilor prevented some online platforms from selling its Essilor or Varilux optic lenses to customers. The authorities added the company refused to deliver its branded lenses as well while also barring the websites from displaying the Essilor logo and trademark. This practice continued for more than a decade, which is why the FCA imposed a hefty fine.
Meanwhile, in a press release, EssilorLuxottica said it is challenging the decision of the FCA. The revealed its intention to file an appeal as it strongly disagrees with the regulators’ decision.
“EssilorLuxottica acknowledges that the French competition authority (FCA) has published today a decision concerning Essilor International,” the French-Italian Ray-Ban manufacturer said. “EssilorLuxottica firmly believes in the legality of its practices and in the relevancy of distributing specific segments of prescription products under conditions that enable us to ensure that consumers can get the best vision correction that is required by their individual vision needs.”
EssilorLuxottica further reiterated that its business practices were fully compliant with the competitive and regulatory conditions in the mentioned period. For its appeal, the firm is confident that it will be able to prove that the FCA’s decision is groundless.


Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 



